Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.34% on December 30, with Wanze Co., Ltd. leading the losses. The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1]. Group 1: Market Performance - The biopharmaceutical sector's performance showed mixed results, with individual stocks experiencing varying degrees of gains and losses. Notably, Aidi Pharmaceutical saw a rise of 4.10% to close at 15.98, while Wanze Co., Ltd. fell by 6.76% to 21.94 [1][2]. - The trading volume for Aidi Pharmaceutical was 93,900 shares, with a transaction value of 150 million yuan, indicating strong investor interest [1]. Group 2: Capital Flow - The biopharmaceutical sector faced a net outflow of 330 million yuan from institutional investors, while retail investors contributed a net inflow of 349 million yuan, suggesting a shift in investor sentiment [2]. - The data indicates that while institutional investors withdrew funds, retail investors were more active in purchasing shares within the sector [2][3]. Group 3: Individual Stock Analysis - Ganne Pharmaceutical experienced a net outflow of 34.73 million yuan from institutional investors, while retail investors showed a net inflow of 129.36 million yuan, reflecting a divergence in investment strategies [3]. - Other notable stocks included Huashan Biological, which had a net inflow of 430.99 million yuan from institutional investors, indicating positive sentiment towards its performance [3].

Market Overview - The Shanghai Composite Index closed at 3940.67 points, above the annual line, with a gain of 0.53% [1] - The total trading volume of A-shares reached 15,224.97 million yuan [1] Stocks Breaking Annual Line - A total of 145 A-shares have surpassed the annual line today, with notable stocks including: - Supcon Test (300887) with a deviation rate of 15.30% - New Jingang (300629) with a deviation rate of 10.60% - Yongyue Technology (603879) with a deviation rate of 9.68% [1] Deviation Rate Rankings - The top stocks with significant deviation rates from the annual line include: - Supcon Test: Today's price increased by 19.95% with a turnover rate of 15.61% [1] - New Jingang: Today's price increased by 20.02% with a turnover rate of 23.76% [1] - Yongyue Technology: Today's price increased by 10.09% with a turnover rate of 5.48% [1] Additional Notable Stocks - Other stocks that have recently crossed the annual line include: - Zhenzhen Technology (003007) with a deviation rate of 8.41% and a price increase of 9.99% [1] - Jun Da Co., Ltd. (002865) with a deviation rate of 6.95% and a price increase of 10.01% [1] - Daye Co., Ltd. (603278) with a deviation rate of 6.60% and a price increase of 9.98% [1]

Core Viewpoint - Dongbao Bio announced that its major shareholder, Hainan Bainasengyuan Technology Co., Ltd., has pledged 33.3354 million shares, which accounts for 66.5958% of its holdings and 3.7398% of Dongbao Bio's total share capital. The pledge is for funding the construction of a project in Hainan, with Citic Securities as the pledgee [1]. Summary by Category - **Shareholder Actions** - Hainan Bainasengyuan Technology Co., Ltd. pledged 33.3354 million shares [1] - The pledged shares represent 66.5958% of the shareholder's total holdings [1] - The pledged shares account for 3.7398% of Dongbao Bio's total share capital [1] - **Pledge Details** - The pledge commenced on December 12, 2025 [1] - The purpose of the pledge is to meet funding needs for a project in Hainan [1] - Citic Securities is the designated pledgee [1]

| | | | | 是否为控股股 | | | 占东宝生 | 是否 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 名称 | 东或第一大股 东及其一致行 | 本次质押数 | 占其所持股 | 物总股本 | 为限 | 为补 充质 | 质押 起始日 | 质押 到期日 | 质权人 | 质押用途 | | | 动人 | 量(股) | 份比例(%) | 比例 (%) | 售股 | 押 | | | | | | | | 10,000,000 | 29.9981 | 1.6846 | 否 | 否 | 年 2025 12 月 日 | 解除质押 日止 | | | | | | | | | | | 12 | | 中信建 | 海南项目 | | 海南百纳盛远科 | 否 | 7,800,000 | 23.3985 | 1.3140 | 否 | 否 | 2025 年 12 | 解除质押 | 投证券 | 建设资金 | | 技有限公司 | | | | | | | 月 日 16 | 日止 | 股份有 | 需求 | | | | ...

Core Insights - The concept of plant-based meat continues to gain momentum, leading to significant stock price increases for companies like Jinzi Ham and Haixin Food, both of which reached their daily price limits [1] - Other companies in the sector, such as Double Tower Food, Huabao Co., and Dongbao Bio, also experienced notable stock price increases, indicating a broader market trend towards plant-based meat products [1] Company Performance - Jinzi Ham and Haixin Food both achieved a daily limit increase in their stock prices, reflecting strong investor interest and confidence in the plant-based meat market [1] - Double Tower Food, Huabao Co., and Dongbao Bio followed suit with their stock prices rising, showcasing a collective positive response from the market towards the plant-based meat industry [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

证券代码：300239 证券简称：东宝生物 公告编号：2025-070 债券代码：123214 债券简称：东宝转债 1、公司未在下列期间内回购公司股份： 包头东宝生物技术股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 包头东宝生物技术股份有限公司(以下简称"东宝生物"或"公司")于2025 年1月3日召开第九届董事会第八次会议、第九届监事会第七次会议，审议通过了 《关于回购公司股份方案的议案》，使用公司自有资金和/或自筹资金以集中竞 价交易方式或法律法规允许的方式回购公司已发行的人民币普通股(A股)股票， 回购的公司股份用于实施员工持股计划或股权激励。本次回购股份不低于人民币 5,000万元(含)，且不超过人民币10,000万元(含)，具体回购资金总额以回购期限 届满时或者回购股份实施完毕时实际回购股份使用的成交资金总额为准。本次回 购价格不超过人民币8.00元/股(含)，本次回购股份的实施期限自公司董事会审议 通过回购股份方案之日起12个月内。因公司实施2024年度权益分派，公司本次回 购价格上限由不超过人民币8.0 ...

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]

Group 1 - Dongbao Biological experienced a stock price increase of 7.04%, reaching 5.93 CNY per share, with a trading volume of 87.45 million CNY and a turnover rate of 2.63%, resulting in a total market capitalization of 3.52 billion CNY [1] - The company, founded on March 12, 1997, and listed on July 6, 2011, is located in Baotou, Inner Mongolia, and specializes in the research, production, and sales of gelatin products and low molecular weight collagen [1] - The main revenue composition of Dongbao Biological includes capsule business (54.13%), gelatin products and by-products (37.30%), collagen business (7.81%), organic fertilizer (0.53%), and others (0.22%) [1] Group 2 - Among the top ten circulating shareholders of Dongbao Biological, one fund from GF Fund Management, GF Jufeng Mixed A (270005), entered the list in the third quarter, holding 4.52 million shares, which accounts for 0.77% of the circulating shares [2] - The estimated floating profit for GF Jufeng Mixed A today is approximately 1.76 million CNY [2] - GF Jufeng Mixed A was established on December 23, 2005, with a current scale of 3.37 billion CNY, and has achieved a year-to-date return of 30.78%, ranking 1994 out of 8136 in its category [2]

Group 1 - The company, Dongbao Biological (300239), primarily engages in the research, production, and sales of gelatin, collagen, hollow capsules, and their derivatives [1] - The company has clarified that it does not involve itself in the rare earth sector [1]